The short version of thymosin alpha 1 fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2025-10-14. Anything still debated is marked as such rather than presented as settled.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, which separates the target peptide from truncated or chemically modified byproducts. Mass spectrometry confirms the expected molecular mass and can indicate acetylation state or sequence errors. Amino acid analysis and peptide mapping supply complementary sequence-level information, while endotoxin testing is relevant for preparations intended for cell or animal work. Purity figures reported by suppliers refer to the method used and are not directly comparable across laboratories unless conditions are stated.
Lyophilized material is typically treated as a hygroscopic solid that should be brought to room temperature before the container is opened, which limits condensation on the powder. Reconstitution is commonly done with sterile water or a buffered diluent, and gentle mixing is preferred over vigorous agitation to reduce foaming and surface adsorption. Because peptides can bind to plastic and glass, diluents containing a small amount of carrier protein are sometimes used in laboratory work. Working solutions are generally aliquoted and prepared fresh rather than subjected to repeated freezing and thawing.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
The molecule consists of 28 amino acid residues with an acetyl group attached to the N-terminal serine. Its sequence is acidic overall, with several glutamic and aspartic acid residues distributed along the chain and no cysteine, so disulfide bridges do not form. The peptide carries a net negative charge at physiological pH. Because the N-terminus is blocked, the intact molecule resists degradation by many aminopeptidases, which contributes to its stability in biological fluids.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Thymosin alpha-1 is a synthetic peptide of 28 amino acid residues that corresponds to a naturally occurring fragment first isolated from thymus tissue. Its chain is acetylated at the amino terminus, a modification that shields the peptide from rapid cleavage by aminopeptidases. The molecule carries a net negative charge at physiological pH and dissolves freely in water. Researchers classify it as an immune-modulating agent rather than a classical hormone, because it acts on several cell types of both the innate and the adaptive immune system.
Most published studies on thymosin alpha-1 report changes in immune measurements rather than clinical outcomes, and findings differ across designs and populations. Whether the peptide signals through one defined receptor or through several less specific interactions remains an open question. Its reported circulation half-life of a few hours complicates comparison of dosing schedules across trials. Mechanistic claims are frequently drawn from isolated cell cultures, and how far those results extend to whole organisms is unresolved.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids whose sequence matches the amino-terminal region of prothymosin alpha. The chain is acetylated at its first residue and contains one disulfide bridge between two cysteine residues, which folds the molecule into a compact loop. Its molecular formula, C129H215N33O55, corresponds to a monoisotopic mass of roughly 3,106 daltons. Material used in laboratories is made by solid-phase synthesis rather than isolated from animal tissue.
Within the immune system, the peptide acts on several cell types rather than a single target. Reported activities include promotion of T-cell maturation, enhancement of natural killer cell activity, and modulation of cytokine production by dendritic cells and macrophages. Some of these effects appear to operate through toll-like receptor signaling, though the precise receptor-level mechanism remains debated. Whether the observed immune changes translate into clinical benefit is a separate question and depends on the indication studied.
The peptide was described in the 1970s as a component of thymic extracts, and early research focused on restoring immune function in immunodeficiency states. A synthetic version entered clinical development in the 1980s and is approved as a drug in several countries for conditions such as chronic hepatitis B and certain immunodeficiencies. Approval status varies widely by jurisdiction, and in the United States it is not an approved therapeutic. Regulatory and clinical positions differ, so statements about efficacy should be tied to specific indications and studies.
Thymosin alpha-1 is a synthetic peptide of 28 amino acids, corresponding to the N-terminal fragment of prothymosin alpha. Its sequence begins with acetylation at the N-terminus, a modification that affects stability and receptor interaction. The peptide is acidic, with a calculated isoelectric point near 4.2, and carries no disulfide bonds, so its secondary structure is largely flexible in solution. Molecular mass is approximately 3108 daltons. The native form was first isolated from bovine thymus tissue, while pharmaceutical material is produced by solid-phase peptide synthesis.
=== Towards type IV === Zoltan Galántai notes that neither Kardashev nor Sagan thought to extend the scale and define a Type IV (which would use the energy of an entire universe). They simply did not envision a civilization capable of manipulating its environment on the largest possible scale (about 14 billion parsecs). The concept of a Type IV supercivilization approaches divine possibilities, enabling the creation of, and travel through, alternate universes of such a civilization's own design, although the latter possibility is reserved for a Type V civilization by Carrigan. The fraction of energy captured by a civilization capable of powering itself on a black hole could also be used to classify civilizations.
The ability of yeast to convert sugar into ethanol has been harnessed by the biotechnology industry to produce ethanol fuel. The process starts by milling a feedstock, such as sugar cane, field corn, or other cereal grains, and then adding dilute sulfuric acid, or fungal alpha amylase enzymes, to break down the starches into complex sugars. A glucoamylase is then added to break the complex sugars down into simple sugars. After this, yeasts are added to convert the simple sugars to ethanol, which is then distilled off to obtain ethanol up to 96% in purity. Saccharomyces yeasts have been genetically engineered to ferment xylose, one of the major fermentable sugars present in cellulosic biomasses, such as agriculture residues, paper wastes, and wood chips. Such a development means ethanol can be efficiently produced from more inexpensive feedstocks, making cellulosic ethanol fuel a more competitively priced alternative to gasoline fuels.
Forensic limnology is the analysis of evidence collected from crime scenes in or around fresh-water sources. Examination of biological organisms, in particular diatoms, can be useful in connecting suspects with victims. Forensic linguistics deals with issues in the legal system that requires linguistic expertise. Forensic meteorology is a site-specific analysis of past weather conditions for a point of loss. Forensic metrology is the application of metrology to assess the reliability of scientific evidence obtained through measurements Forensic microbiology is the study of the necrobiome. Forensic nursing is the application of Nursing sciences to abusive crimes, like child abuse, or sexual abuse. Categorization of wounds and traumas, collection of bodily fluids and emotional support are some of the duties of forensic nurses. Forensic odontology is the study of the uniqueness of dentition, better known as the study of teeth. Forensic optometry is the study of glasses and other eyewear relating to crime scenes and criminal investigations. Forensic pathology is a field in which the principles of medicine and pathology are applied to determine a cause of death or injury in the context of a legal inquiry. Forensic podiatry is an application of the study of feet footprint or footwear and their traces to analyze scene of crime and to establish personal identity in forensic examinations. Forensic psychiatry is a specialized branch of psychiatry as applied to and based on scientific criminology. Forensic psychology is the study of the mind of an individual, using forensic methods.
== Development == Sally Green submitted Half Bad to an agent in January 2013; in March, editorial director Ben Horslen acquired the manuscript for Penguin Books children's imprint Puffin Books, billing it "the book of the Bologna Children's Book Fair" after a six-figure bidding war. In the run up to its publication in the UK on March 3, 2014, international rights to Half Bad sold rapidly; within 13 weeks of acquisition, it had sold in 25 territories; by November 2013, 36. On publication day, it broke the Guinness World Record for 'Most Translated Book by a Debut Author, Pre-publication' with 45 different translations.
The gallbladder is a hollow part of the biliary tract that sits just beneath the liver, with the gallbladder body resting in a small depression. It is a small organ where the bile produced by the liver is stored, before being released into the small intestine. Bile flows from the liver through the bile ducts and into the gall bladder for storage. The bile is released in response to cholecystokinin (CCK), a peptide hormone released from the duodenum. The production of CCK (by endocrine cells of the duodenum) is stimulated by the presence of fat in the duodenum. It is divided into three sections, a fundus, body and neck. The neck tapers and connects to the biliary tract via the cystic duct, which then joins the common hepatic duct to form the common bile duct. At this junction is a mucosal fold called Hartmann's pouch, where gallstones commonly get stuck. The muscular layer of the body is of smooth muscle tissue that helps the gallbladder contract, so that it can discharge its bile into the bile duct. The gallbladder needs to store bile in a natural, semi-liquid form at all times. Hydrogen ions secreted from the inner lining of the gallbladder keep the bile acidic enough to prevent hardening. To dilute the bile, water and electrolytes from the digestion system are added. Also, salts attach themselves to cholesterol molecules in the bile to keep them from crystallising. If there is too much cholesterol or bilirubin in the bile, or if the gallbladder does not empty properly the systems can fail.
Sources: en.wikipedia.org
Instead, the German forces were equipped with US nuclear weapons. On 13 November 1957, in the Konzerthaus (Concert Hall) in Vienna, Hahn warned of the "dangers of A- and H-bomb-experiments", and declared that "today war is no means of politics anymore – it will only destroy all countries in the world". His highly acclaimed speech was transmitted internationally by the Austrian radio, Österreichischer Rundfunk (ÖR). On 28 December 1957, Hahn repeated his appeal in an English translation for the Bulgarian Radio in Sofia, which was broadcast in all Warsaw pact states.
== Notable alumni == Tassaduq Hussain Jillani, 21st Chief Justice of Pakistan Samar Mubarakmand, nuclear physicist Nawabzada Nasrullah Khan, politician Makhdoom Sajjad Hussain Qureshi, former Governor of Punjab Inzamam-ul-Haq, cricketer and former captain of the Pakistan national cricket team Syed Jamshed Ali, former judge of the Supreme Court of Pakistan Faiz Mohammad Khan, medical physicist specialising in radiation oncology Mazhar Kaleem, novelist Tauqeer Nasir, actor and former director-general of the Pakistan National Council of the Arts Muhammad Ali, Lollywood actor Mohsin Naqvi, Urdu poet Irshad Hussain, chemist and nanomaterials scientist Khalid Masood Khan, poet and columnist Ehsan Wyne, lawyer and politician
Bradykinin is rapidly inactivated in the circulating blood, and it disappears completely in a single pass through the pulmonary circulation. Angiotensin I also disappears in the pulmonary circulation because of its conversion to angiotensin II. Furthermore, angiotensin II passes through the lungs without any loss. The inactivation of bradykinin and the conversion of angiotensin I to angiotensin II in the lungs was thought to be caused by the same enzyme. In 1970, Ng and Vane, using BPF provided by Ferreira, showed the conversion is inhibited during its passage through the pulmonary circulation. BPFs are members of a family of peptides whose potentiating action is linked to inhibition of bradykinin by ACE. Molecular analysis of BPF yielded a nonapeptide BPF teprotide (SQ 20,881), which showed the greatest ACE inhibition potency and hypotensive effect in vivo. Teprotide had limited clinical value as a result of its peptide nature and lack of activity when given orally. In the early 1970s, knowledge of the structure-activity relationship required for inhibition of ACE was growing. David Cushman, Miguel Ondetti and colleagues used peptide analogs to study the structure of ACE, using carboxypeptidase A as a model. Their discoveries led to the development of captopril, the first orally-active ACE inhibitor, in 1975. Captopril was approved by the United States Food and Drug Administration in 1981. The first nonsulfhydryl-containing ACE inhibitor, enalapril, was approved four years later. At least 8 other ACE inhibitors have since been marketed.
Manufactured cigarettes represent the most prevalent form of tobacco consumption globally, accounting for approximately 70% to 80% of all tobacco use. In addition to the inherent risks of tobacco use, manufactured cigarettes have specific engineering and chemical modifications that introduce secondary harms. Modern commercial cigarettes utilize filter ventilation (small perforations in the filter), which were historically marketed to reduce tar but actually encourage "compensatory smoking", where users inhale more deeply to maintain nicotine levels. The manufacturing process also incorporates approximately 600 additives, such as ammonia, which is used to "freebase" nicotine for faster absorption into the brain, and sugars that, when burned, produce the carcinogen acetaldehyde. Nearly all manufactured cigarettes in the U.S. and EU are classified as fire-safe cigarettes, which requires manufacturers to add chemicals to the paper to extinguish the cigarette if left unattended. Some studies and consumer reports have linked these treated papers to increased levels of carbon monoxide and naphthalene in the smoke, as well as unique side effects like increased respiratory irritation and headaches compared to other tobacco products.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
Cold storage slows the chemical degradation reactions that occur in solution. Lyophilized powder is more stable than reconstituted liquid and tolerates longer storage periods. Repeated temperature cycling should still be avoided because it can drive aggregation and loss of material.